Portal de Periódicos da CAPES

Ciclosporin in psoriasis clinical practice: an international consensus statement

2004; Oxford University Press; Volume: 150; Issue: s67 Linguagem: Inglês

10.1111/j.0366-077x.2004.05949.x

1365-2133

C.E.M. Griffiths, Louis Dubertret, Charles N. Ellis, A.Y. Finlay, A. F. Finzi, Vincent Ho, A. E. Johnston, A. Katsambas, A-E. Lison, Jean Naeyaert, Hidemi Nakagawa, C. Paul, F. Vanaclocha,

Mast cells and histamine

Journal Article Ciclosporin in psoriasis clinical practice: an international consensus statement Get access C.E.M. Griffiths, C.E.M. Griffiths Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Professor Christopher Griffiths, Dermatology Centre, University of Manchester Irving Building, Hope Hospital, Salford, Manchester, M6 8HD, UK. E‐mail: christopher.griffiths@man.ac.uk. Search for other works by this author on: Oxford Academic Google Scholar L. Dubertret, L. Dubertret Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar C.N. Ellis, C.N. Ellis Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar A.Y. Finlay, A.Y. Finlay Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar A.F. Finzi, A.F. Finzi Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar V.C. Ho, V.C. Ho Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar A. Johnston, A. Johnston Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar A. Katsambas, A. Katsambas Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar A‐E. Lison, A‐E. Lison Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar J.M. Naeyaert, J.M. Naeyaert Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar ... Show more H. Nakagawa, H. Nakagawa Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar C. Paul, C. Paul Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar F. Vanaclocha F. Vanaclocha Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK *Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France †Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA ‡Department of Dermatology, University of Wales College of Medicine, Cardiff, UK §Department of Dermatology, University of Milan, Milan, Italy ¶Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada **Clinical Pharmacology, Barts and The London, University of London, UK ††Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece ‡‡Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany §§Department of Dermatology, Ghent University Hospital, Gent, Belgium ¶¶Department of Dermatology, Jichi Medical School, Tochigi, Japan ***Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France †††Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 150, Issue s67, 1 May 2004, Pages 11–23, https://doi.org/10.1111/j.0366-077X.2004.05949.x Published: 01 May 2004